• March 15, 2023 - The data has been updated in Inxight and Stitcher, based on the December 2022 G-SRS Update. See the details about the data sources included, and a summary of recent changes on the About page.

The National Center for Advancing Translational Sciences (NCATS) has developed Inxight Drugs as a comprehensive portal for drug development information. NCATS Inxight Drugs contains information on ingredients in medicinal products, including:

US Approved Drugs: 2620

Marketed Drugs: 11847

Investigational Drugs: 9748

All Substances: 144045

NCATS Inxight Drugs incorporates and unifies a wealth of data, including manually curated data supplied by the FDA and private companies, and provides marketing and regulatory status, rigorous drug ingredient definitions, biological activity, clinical use, and more.

NCATS has developed Inxight data resources to facilitate translational research. All facts appearing in these datasets are in the public domain and may be reproduced or copied without NCATS permission.
If you use Inxight in your work, please cite our manuscript:

Vishal B. Siramshetty, Ivan Grishagin, Ðắc-Trung Nguyễn, Tyler Peryea, Yulia Skovpen, Oleg Stroganov, Daniel Katzel, Timothy Sheils, Ajit Jadhav, Ewy A Mathé, Noel T. Southall
Nucleic Acids Research 2022, 50(D1), D1307-D1316, 10.1093/nar/gkab918

Please note that these datasets are continually updated and refreshed, and users are encouraged to update derivative works frequently.

A supplementary resource — Novel FDA Drug Approvals — features new molecules approved by the FDA by year since 1941.
Comprehensive data are provided for all years since 2010; each molecule has a summary, clinical development timeline, product, active ingredients, target, condition, and details about the review process used by the FDA to approve the drug.